BusinessPostCorner.com
No Result
View All Result
Monday, July 7, 2025
  • Home
  • Business
  • Finance
  • Accounting
  • Tax
  • Management
  • Marketing
  • Crypto News
  • Human Resources
BusinessPostCorner.com
  • Home
  • Business
  • Finance
  • Accounting
  • Tax
  • Management
  • Marketing
  • Crypto News
  • Human Resources
No Result
View All Result
BusinessPostCorner.com
No Result
View All Result

Eli Lilly raises outlook on bumper sales of diabetes and weight loss drugs

August 8, 2024
in Finance
Reading Time: 2 mins read
A A
0
Eli Lilly raises outlook on bumper sales of diabetes and weight loss drugs
ShareShareShareShareShare

Unlock the Editor’s Digest for free

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.

Eli Lilly raised its revenue forecast for 2024, sending its shares soaring, as the world’s biggest drugmaker by market value continues to benefit from bumper sales of its blockbuster diabetes and weight loss drugs.

The Indianapolis-based company on Thursday increased its full-year sales guidance by $3bn to between $45.4bn and $46.6bn, citing the “strong performance of Mounjaro and Zepbound”, its new class of diabetes and weight loss medicines known as GLP-1s.

Revenue in the second quarter increased 36 per cent year on year to $11bn, while net income rose 68 per cent to $2.97bn, beating analysts’ expectations on both counts.

The sales boosts suggest that Eli Lilly has an edge over rival weight loss drugmaker Novo Nordisk in the race to boost manufacturing capacity to meet demand for a market that Goldman Sachs analysts estimate could be worth $130bn in peak annual sales. The Danish drugmaker’s sales came in below analyst expectations on Wednesday because of manufacturing challenges. 

Eli Lilly chief executive David Ricks said the better than expected sales in its most recent quarter were driven by the GLP-1 medicines as the drugmaker “advanced our manufacturing expansion agenda” to meet the huge demand for the medicines. Increased pricing power for Mounjaro also boosted revenues, the company said.

Sales of new products, which include the GLP-1 medicines, rose $3.5bn to $4.5bn. Sales of diabetes drug Mounjaro totalled $3.1bn in the second quarter, while revenues from anti-obesity medication Zepbound reached $1.2bn.

Evan Seigerman, a pharma industry analyst at BMO Capital Markets, said the quarterly earnings suggested that Eli Lilly was besting Novo Nordisk and “pulling ahead in the metabolic duopoly”.

Eli Lilly’s shares jumped more than 9 per cent shortly after Wall Street’s opening bell on Thursday, taking the pharmaceutical group’s market capitalisation back above $800bn for the first time in a fortnight. The company’s share price has slid in recent weeks as a broader market rotation had investors flocking to cheaper pharmaceutical stocks and undervalued weight loss drugmakers such as Roche.

Last week, four different doses of Mounjaro and Zepbound were removed from a US Food and Drug Administration database tracking drug shortages in a sign that supply constraints have eased. The medicines were listed as “available”, but still remain on the agency’s shortages list.

Rival weight loss drugmaker Novo Nordisk, which manufactures diabetes drug Ozempic and its anti-obesity offshoot Wegovy, on Wednesday reported second-quarter sales that were slightly below analysts’ expectations. That provoked concerns from investors that it was being outmanoeuvred by Eli Lilly in the race to boost manufacturing capacity, resulting in Novo’s shares closing 6.7 per cent lower on the day.

BMO Capital Markets’ Seigerman said in a research note that Eli Lilly’s results were “impressive” and “reflect improving supply dynamics for the company’s [GLP-1] portfolio and higher realised prices for Mounjaro in the US.”

Credit: Source link

ShareTweetSendPinShare
Previous Post

CAS needs to include client education

Next Post

Egg donors warned not to do it for the money as compensation rises

Next Post
Egg donors warned not to do it for the money as compensation rises

Egg donors warned not to do it for the money as compensation rises

Government supporting Lindsey Oil Refinery as 420 jobs at risk

Government supporting Lindsey Oil Refinery as 420 jobs at risk

June 30, 2025
XRP Price Prediction: Despite Recent Slip, Ripple’s Institutional Push Targets  – What to Watch

XRP Price Prediction: Despite Recent Slip, Ripple’s Institutional Push Targets $10 – What to Watch

July 5, 2025
Armanino planning data warehouse service, used AI for development

Armanino planning data warehouse service, used AI for development

July 2, 2025
Serena Williams says talent alone only gets you so far: For career success, like tennis, you have to grind ‘every day’

Serena Williams says talent alone only gets you so far: For career success, like tennis, you have to grind ‘every day’

June 30, 2025
Private healthcare groups criticise ‘minimum’ waiting times for NHS operations

Private healthcare groups criticise ‘minimum’ waiting times for NHS operations

July 2, 2025
CPA develops tools for accountants with dentist, veterinarian clients

CPA develops tools for accountants with dentist, veterinarian clients

July 2, 2025
BusinessPostCorner.com

BusinessPostCorner.com is an online news portal that aims to share the latest news about following topics: Accounting, Tax, Business, Finance, Crypto, Management, Human resources and Marketing. Feel free to get in touch with us!

Recent News

[LIVE] Crypto News Today: Latest Updates for July 7, 2025 – “Fiat Is Hopeless”: Elon Musk Says ‘America Party’ Will Embrace Bitcoin

[LIVE] Crypto News Today: Latest Updates for July 7, 2025 – “Fiat Is Hopeless”: Elon Musk Says ‘America Party’ Will Embrace Bitcoin

July 7, 2025
Trump threatens extra 10% tariff on nations that side with Brics

Trump threatens extra 10% tariff on nations that side with Brics

July 7, 2025

Our Newsletter!

Loading
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • DMCA

© 2023 businesspostcorner.com - All Rights Reserved!

No Result
View All Result
  • Home
  • Business
  • Finance
  • Accounting
  • Tax
  • Management
  • Marketing
  • Crypto News
  • Human Resources

© 2023 businesspostcorner.com - All Rights Reserved!